Annals of Hepatology (Mar 2023)

OP-5 ALCOHOL-ASSOCIATED HEPATITIS IN LATIN AMERICA: RESULTS FROM THE AH-LATIN STUDY

  • Luis Antonio Díaz,
  • Jorge Arnold,
  • Francisco Idalsoaga,
  • Gustavo Ayares,
  • María Ayala-Valverde,
  • Diego Perez,
  • Jaime Gomez,
  • Rodrigo Escarate,
  • Juan Pablo Roblero,
  • Blanca Norero,
  • José Antonio Velarde,
  • Janett Jacobo,
  • Jesús Varela,
  • Scherezada Mejía Loza,
  • Jacqueline Córdova,
  • Rita Silva,
  • Cristina Melo Rocha,
  • Roberta C. Araujo,
  • Gustavo Henrique Pereira,
  • Claudia Couto,
  • Fernando Bessone,
  • Mario Tanno,
  • Gustavo Romero,
  • Manuel Mendizabal,
  • Sebastián Marciano,
  • Melisa Dirchwolf,
  • Pedro Montes,
  • Patricia Guerra Salazar,
  • Geraldine Ramos,
  • Juan Carlos Restrepo,
  • Gabriel Díaz,
  • Luis Guillermo Toro,
  • Enrique Carrera,
  • Brahmania Mayur,
  • Singal Ashwani,
  • Bataller Ramon,
  • Shah Vijay,
  • Kamath Patrick S.,
  • Marco Arrese,
  • Juan Pablo Arab

Journal volume & issue
Vol. 28
p. 101054

Abstract

Read online

Introduction and Objectives: Severe alcohol-associated hepatitis (AH) is an entity with high morbidity and mortality; however, data in Latin America is limited. We aimed to characterize patients hospitalized for AH in a multinational cohort in Latin America. Materials and Methods: Multicenter prospective cohort study. We included patients admitted with severe AH between 2015-2022. Sociodemographic and clinical information was recorded. The analysis included survival analysis using Kaplan-Meier curves. This study was approved by the institutional ethics committee. Results: 470 patients from 24 centers (8 countries: Mexico, Chile, Argentina, Brazil, Peru, Bolivia, Colombia, and Ecuador) were included. Age 49.8 ± 10.6 years, 85.6% of men and 45% had a previous diagnosis of cirrhosis. Median MELD at admission was 26.9 [22-32] points. 26.5% met SIRS criteria and 34.3% had an acute kidney injury (AKI) on admission. Only 36.8% of patients were treated with corticosteroids. Survival at 30 days was 75.0% (95%CI: 70.1-79.3%) and 62.8% (95%CI: 57.1-68.0%) at 90 days. A total of 191 (45.8%) patients presented infections, 31.4% at admission and 24.9% during hospitalization. The most frequent locations of community-acquired infections were respiratory (33.5%), urinary (32.1%), spontaneous bacterial peritonitis (14.9%), and skin (10.5%), while the most frequent pathogens were Escherichia coli (40%), Klebsiella pneumoniae (12%), and Enterococcus (6%). The presence of infection at admission was associated with a decreased survival at 90-days (66.9% versus 48.1%, p=0.0002). AKI at admission was also associated with decreased survival at 90-days (86.8% versus 51.3%, p<0.0001). In the long term, only 3.2% of patients have been transplanted. Conclusions: This multicenter study shows high morbidity and mortality in patients with severe AH, which is comparable to other regions worldwide. The presence of infections and AKI at admission were frequent and were associated with higher mortality. Unfortunately, the access to liver transplantation was extremely low in our cohort.